SASheila T. Angeles-Han

Sheila T. Angeles-Han

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sheila T. Angeles-Han has a total of 454 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Tear‐Based Biomarker Trajectories Associated With Uveitis in Juvenile Idiopathic Arthritis: A Multicenter Prospective Study

    by Ilaria Macorra, Mariia Pavlenko, Mekibib Altaye, Hermine I. Brunner, John Bohnsack, Margaret H. Chang, Ashley M. Cooper, Stefanie Davidson, Alexandra Duell, Bharti Gangwani, et al.

    Objective: The extent of uveitis risk in juvenile idiopathic arthritis (JIA) is based on clinical factors. We aim to compare the trajectories of tear‐based biomarker levels of patients with JIA with and without uveitis. Methods: This prospective multicenter study included children with JIA at risk for uveitis (JIA‐no‐U) and those with JIA‐associated uveitis (JIA‐U). Serial tear samples were collected from each eye by Schirmer strips at enrollment and the first and second follow‐up visits (FU1 and FU2). S100 proteins, cytokines, and chemokines were assayed by Luminex or enzyme‐linked immunosorbent assay and compared between groups. Results: Fifty patients (37 JIA‐no‐U, 13 JIA‐U) contributed 222 samples (150 JIA‐no‐U, 73 JIA‐U). At enrollment, there were no significant differences in biomarker levels between JIA‐U and JIA‐no‐U. During follow‐up of patients with JIA‐U, monocyte chemoattractant protein 1 (MCP‐1) levels increased longitudinally from enrollment to FU1 and FU2 (LS mean ± SE 1.63 ± 0.31 to 2.46 ± 0.31, P = 0.005; and 2.89 ± 0.32, P < 0.0001), and there was a similar increase in CXCL10 (LS mean ± SE 4.39 ± 0.41 to 5.26 ± 0.41, P = 0.030; and 6.51 ± 0.43, P < 0.0001) and interleukin‐8 (IL‐8) levels from enrollment to FU1 and FU2 (LS mean ± SE 3.09 ± 0.30 to 4.25 ± 0.30, P = 0.006; and 4.65 ± 0.32, P ≤ 0.001). In both groups, S100A12 and S100A8/A9 levels increased from enrollment to follow‐up. Conclusion: Longitudinal changes in MCP‐1, CXCL10, and IL‐8 levels in tear fluid in JIA‐U may reflect inflammatory ocular processes and support the role of monocytes and interferon‐related pathways in uveitis. Lack of differences in S100 proteins may reflect systemic inflammation from arthritis. Tear‐based biomarkers may support clinical factors for identifying children with JIA who develop uveitis.

  • Open Access

    Identification and evaluation of 41 risk loci for juvenile idiopathic arthritis informs precision medicine: mechanistic implications of DNA topology and an HLA-A*02:01-ERAP2 interaction

    by Hannah C. Ainsworth, Ekaterina S. Khvatkova, Marc Sudman, Miranda C. Marion, Kaiyu Jiang, John F. Bohnsack, Mary E. Comeau, Patrick M. Gaffney, Johannes-Peter Haas, Timothy D. Howard, et al.

    Juvenile idiopathic arthritis (JIA), the most common class of pediatric rheumatic diseases, can lead to joint damage and extra-articular features including uveitis. Early treatment can improve functional outcomes; but many patients do not respond to first-line treatments. We present a JIA Immunochip-based association analysis of rheumatoid factor-negative polyarticular JIA and oligoarticular JIA. This study spans 3,939 cases and 14,412 controls, including 1,123 cases and 1,356 controls not previously analyzed. We identify 41 (14 novel) JIA risk regions and report a JIA polygenic risk score that also associates with age of onset. Functional mechanisms presented include: a novel interaction between HLA-A*02:01 and ERAP2 , cluster-based approach for functional amino acid discovery within HLA-DRB1, and sequence-dependent DNA topology for variant prioritization. We present a comprehensive list of curated gene-drug/small molecule interactions for clinically focused studies. These findings provide a deepened understanding of the genetics of JIA and potential mechanisms to inform precision medicine.

  • Open Access

    Single nucleus RNA sequencing of juvenile dermatomyositis skeletal muscle identifies altered angiogenic signaling

    by Casey O. Swoboda, Carmy Forney, Cristofer Calvo, Lucinda P. Lawson, Hilal Cevik, Kairavee Thakkar, Caitlin Treuting, Stephen N. Waggoner, Cheryl Bayart, Meredith P. Schuh, et al.

    Juvenile dermatomyositis (JDM) is a chronic multisystem vasculopathy and inflammatory myopathy characterized by proximal muscle weakness, distinct rash, and risk of complications such as calcinosis cutis, skin ulceration, and mortality. Molecular insight from diagnostic muscle biopsy histology is limited, and the mechanistic pathoetiology of JDM remains poorly defined. We used single nuclei transcriptomics to assess muscle samples from patients with newly diagnosed treatment-naïve JDM. As a control, we assessed muscle samples from patients with congenital (nemaline) myopathy (CM), a non-inflammatory disorder. A total of 25,794 high quality nuclei were analyzed and clustered into various muscle-resident or infiltrating cellular populations. JDM tissue was characterized by an enriched interferon (IFN) response signature across endothelial, stromal, and immune cell compartments. Endothelial and perivascular populations showed increased inflammatory and angiogenic programs. Intercellular communication inference analysis identified dysregulated vascular endothelial growth factor (VEGF)-related signaling involving endothelial, stromal, and myonuclear populations as a possible mechanism for myonuclear-driven modulation of the muscle microvasculature. Spatial RNA in situ hybridization supported increased expression of selected IFN responsive and angiogenesis signaling genes in JDM tissue. Collectively, these data provide a cell type-resolved view of treatment-naïve JDM muscle and highlight vascular and IFN pathways for follow-up in larger cohorts.

  • What is the best way to plan a 12-month clinical drug trial in JIA associated uveitis?

    by Ivan Foeldvari, Ameenat Solebo, Sheila T. Angeles-Han, Agnes Galbo Brost, Joke de Boer, Jesus Díaz-Cascajosa, Mia Glerup, Helene Ingels, Jens Klotsche, Viera Koopman-Kalinina Ayuso, et al.

    Juvenile idiopathic arthritis associated anterior uveitis (JIA-U) is the most common extraarticular manifestation of JIA. There are no published proposed criteria or outcome measures for a 12-month clinical trial for JIA-U. Our expert group, the Multinational Interdisciplinary Working Group for Uveitis in Childhood (MIWGUC) reviewed the previous trials, the quality-of-life instruments, biomarkers and the patient perspective. Based on an expert consensus a proposal for a future clinical trial was developed, to provides a foundation for the standardization of outcome measures and trial design in JIA-U. By integrating clinical, imaging, biomarker, and patient-reported outcomes into a unified framework, we aim to accelerate evidence based therapeutic development and improve long-term care for children affected by anterior uveitis. A key measure of primary outcome is the anterior chamber cell number, which has intra-observer and inter-observer variation. New techniques that are objective and decrease the variation of the assessment are emerging. anterior segment Optical Coherence Tomography(OCT) is an innovative imaging technology to a assess the number of anterior chamber cells OCT. The flare meter is an additional assessment although not yet widely used.

  • Open Access

    Validation of the Pediatric Arthritis Ultrasound Scoring System for the Elbow, Wrist, and Finger Joints in Children With Juvenile Idiopathic Arthritis

    by Patricia Vega‐Fernandez, Pinar Ozge Avar‐Aydin, Kelly Rogers, Daniel J. Lovell, Jennifer Huggins, Alexei Grom, Hermine I. Brunner, Grant S. Schulert, Sheila T. Angeles‐Han, Mekibib Altaye, et al.

    Objective: We aimed to validate the Pediatric Arthritis Ultrasound Scoring System (PAUSS) for upper extremity joints in children with juvenile idiopathic arthritis (JIA). Methods: Children with JIA were evaluated for elbow, wrist, or finger arthritis by clinical examination (CE) and musculoskeletal ultrasound (MSUS) with images scored according to the joint‐specific PAUSS. A subset of children received contrast‐enhanced magnetic resonance imaging (ceMRI) of the affected joint(s). The performance of the PAUSS as a measure of arthritis activity was compared to CE and ceMRI, using ceMRI as the reference standard. Results: Seventy‐five children contributed 44 elbows, 55 wrists, and 106 fingers for MSUS and 15 elbows, 16 wrists, and 40 fingers for ceMRI. B‐mode PAUSS scores for the finger joints demonstrated moderate correlations with CE findings of arthritis, and the PAUSS‐elbow noted a strong correlation. PAUSS scores for all joints showed a sensitivity of 75% to 94% in detecting synovitis when compared to ceMRI and good to excellent diagnostic accuracy for elbow and finger arthritis. The addition of MSUS to CE markedly improved the sensitivity of CE to 92% to 100%. The PAUSS and ceMRI scores for assessment of disease severity had strong correlation for each specific joint ( r = 0.65–0.84, P ≤ 0.005). Conclusion: There is moderate to high sensitivity and diagnostic accuracy of the PAUSS in detecting synovitis in elbow, wrist, and finger joints, as well as a strong correlation of the PAUSS severity scores with the ceMRI severity scores, providing strong support that the PAUSS enhances the clinical assessment of disease activity in children with JIA.


  • Monitoring of Juvenile Idiopathic Arthritis–Associated Uveitis in Long‐Term Disease Remission: Consensus‐Based Recommendations From the Multinational Interdisciplinary Working Group for Uveitis in Childhood

    by Ivan Foeldvari, Ameenat Solebo, Harry Petrushkin, Sheila T. Angeles‐Han, Regitze Bangsgaard, Joan Calzada‐Hernández, Tamas Constantin, Joke de Boer, Jesus Díaz‐Cascajosa, Mia Glerup, et al.

    Objective: We aimed to develop consensus‐based recommendations for the monitoring of children with juvenile idiopathic arthritis–associated uveitis (JIAU) in long‐term remission, addressing the absence of international guidance on monitoring schedules for these children and young people.Methods: The Multinational Interdisciplinary Working Group for Uveitis in Childhood convened experts from 10 countries, including pediatric rheumatologists and ophthalmologists, alongside parents of affected children. A review of key longitudinal cohort studies informed a structured consensus process comprising discussion, recommendation development, and voting for adoption, with a consensus threshold of ≥80% needed for adoption. Recommendation development focused on three principal questions: stratification of the risk of poor outcomes, the natural history of JIAU postremission, and the impact of delayed examination.Results: The group established several key recommendations, including a standard monitoring frequency of every 4 months for the first four years following medication cessation, ongoing assessments for patients with structural complications, and low‐frequency monitoring every 6 months for those in stable, drug‐free remission for over four years. There was unanimous agreement on these recommendations.Conclusion: These consensus‐based recommendations provide a framework for monitoring children with JIAU in remission, enhancing the quality of care and optimizing resource use in eye health services. Ongoing research is essential to refine these guidelines as new evidence emerges regarding biomarkers and imaging techniques for disease recurrence.


  • Physician's global assessment of disease activity in juvenile idiopathic arthritis: consensus-based recommendations from an international task force

    by Veronika Rypdal, Hermine I. Brunner, Brian M. Feldman, Nicolino Ruperto, Amita Aggarwal, Sheila T. Angeles-Han, Maria Backström, Erin Balay-Dustrude, Claudia Bracaglia, Fabrizio De Benedetti, et al.


  • 25 Years of Biologics for the Treatment of Pediatric Rheumatic Disease: Advances in Prognosis and Ongoing Challenges

    by Michael Shishov, Pamela F. Weiss, Deborah M. Levy, Joyce C. Chang, Sheila T. Angeles‐Han, Ekemini A. Ogbu, Kabita Nanda, Tina M. Sherrard, Ellen Goldmuntz, Daniel J. Lovell, et al.

    There are over 100 rheumatic diseases and approximately 300,000 children with a pediatric rheumatic disease (PRD) in the United States. The most common PRDs are juvenile idiopathic arthritis (JIA), childhood‐onset systemic lupus erythematosus (cSLE), and juvenile dermatomyositis (JDM). Effective and safe medications are essential because there are generally no cures for these conditions. Etanercept was the first biologic therapy for the treatment of JIA, approved in 1999. Since then, other biologic disease‐modifying antirheumatic drugs (bDMARDs) and targeted synthetic disease‐modifying antirheumatic drugs (tsDMARDs) blocking relevant immunologic pathways have been approved for the treatment of JIA, resulting in a marked improvement of disease prognosis. Conversely, there is only one bDMARD that has been approved for cSLE, but none are approved for the treatment of JDM. Lack of approved therapeutic options, with established dosing regimens and known efficacy and safety, remains a central challenge in the treatment of all PRDs, including autoinflammatory diseases, and for complications of PRDs. This review provides an overview of bDMARD and tsDMARD treatments studied for the treatment of various subtypes of JIA, summarizes information from bDMARD studies in other PRDs, with a focus on pivotal trials that led to regulatory approvals, and highlights improved outcomes in patients with JIA with the reception of these newer medications. Further, we outline barriers and challenges in the treatment of other PRDs. Last, we summarize the current regulatory landscape for bDMARD studies and medication approvals for patients with PRDs.


  • Open Access

    Achieving Medication‐Free Remission in Patients With Juvenile Dermatomyositis

    by Ilaria Maccora, Hermine I. Brunner, Amy Cassedy, Mekibib Altaye, Megan Quinlan‐Waters, Daniel J. Lovell, Alexei Grom, Sheila T. Angeles‐Han

    Objective: Prognostic factors associated with medication discontinuation in children with juvenile dermatomyositis (JDM) remain largely elusive. We aim to identify the predictors of medication‐free remission (MFR) in children with JDM.Methods: In this retrospective study, patients diagnosed with JDM according to Peter & Bohan criteria and followed for ≥18 months at a tertiary care center from 2006 through 2022 were included. Data extracted included demographics, physical examination, laboratory results, and medications. MFR was defined as inactive JDM after discontinuation of all systemic immunosuppressives for ≥6 months, in line with international consensus guidelines for trials of therapies in idiopathic inflammatory myopathies. A two‐sided P < 0.05 was considered statistically significant.Results: Of 55 patients with JDM (63.6% female, age median [interquartile range (IQR)] 6 [3.5–12] years), 29 (52.7%) achieved MFR after a median (IQR) of 33 (22.5–55.2) months. MFR was more common in those who were younger at JDM diagnosis (median 5 vs 8 years, P = 0.008), had early resolution of disease activity (median 11 vs 18 months, P < 0.001), and presented with Gottron papules (χ2 = 5.25; P = 0.022) and elevated lactate dehydrogenase (χ2 = 4.82, P = 0.028). Diagnosis of JDM before 5 years old (odds ratio 4.5, 95% confidence interval [CI] 1.2–16.7) was the only predictor of MFR in our multivariate model (area under the curve 0.65, 95% CI 0.53–0.76).Conclusion: Half of our patients with JDM achieved MFR. Age at JDM diagnosis may be an important predictor of achieving MFR.


  • Candidate Tear-Based Uveitis Biomarkers in Children with JIA Based on Arthritis Activity and Topical Corticosteroid Use

    by Ilaria Maccora, Mekibib Altaye, Kenneth D. Greis, Hermine I. Brunner, Alexandra Duell, Wendy D. Haffey, Tiffany Nguyen, Megan Quinlan-Waters, Grant S. Schulert, Alyssa Sproles, et al.

    Uveitis is an inflammatory ocular disease secondary to disruption of the retinal pigmented epithelium (RPE) and blood retinal barrier (BRB). Known clinical factors do not accurately predict uveitis risk in Juvenile Idiopathic Arthritis (JIA). Tear fluid is easily obtained for biomarker study. We aim to identify tear-based markers associated with the presence of uveitis in children with JIA. In a cross-sectional comparative cohort study, tears were collected by Schirmer strips from children with oligoarticular JIA-associated uveitis (JIA-U) and JIA without uveitis (JIA-no-U). A tandem isotope tagging (iTRAQ and TMT) strategy was used for relative quantitation via nanoLC-MS/MS to quantify proteins in the affected eye. Log transformed relative protein abundance of protein levels was compared between groups using Wilcoxon exact test. We explored the influence of arthritis activity and topical corticosteroids (CS) use on protein levels. STRING analysis was performed. Tear samples of 14 JIA-U and 14 JIA-no-U patients were analyzed. Thirteen proteins were differentially expressed between both groups. Stratified analysis based on arthritis activity (inactive arthritis) and topical CS (off CS) showed that alpha-2-macroglobulin (p = 0.012), apolipoprotein A1 (p = 0.036), S100A9 (p = 0.05), haptoglobin (p = 0.066), and transthyretin (p = 0.066) consistently differentiated between both groups. On STRING analysis, these proteins were associated with the RPE, BRB, and inflammation. Importantly, we identified proteins involved in the RPE, BRB, and immune response that were differentially abundant in the tears of children with JIA-U compared to JIA-no-U, regardless of arthritis activity or topical CS. Candidate tear-based biomarkers may represent a non-invasive means to detect uveitis.